Intermediate Tai Chi

Patient Newsletter 2025 April

Solid Tumor, TP-CA-007 “ARIES 006”

A Biobank Registry Platform Study in Oncology Patients with any solid tumor prior to starting treatment with any ADC

Lymphoma, GOLSEEK-1 CA073-1020

A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma

Prostate, TP-CA-007 “ARIES 005”

A Biobank Registry Platform Study in Oncology Patients with advanced or metastatic disease (Stage 3B, 3C, 4) castration resistant prostate cancer

Lung, D419ML00003 “ TRITON”

A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Lung, D702BC00001 “Artemide-Lung02”

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Esophageal, TP-CA-007 “Aries”

A Biobank Registry Platform Study in Oncology Patients with advanced or metastatic disease (Stage 3B, 3C, 4) gastric, esophageal, or gastroesophageal junction (GEJ) cancer

Colorectal, MCLA-158-CL01 “MERUS”

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in mCRC

Breast, A012301 "LOTAM"

A randomized phase III clinical trial of low-dose Tamoxifen for selected patients with molecular low-risk early-stage breast cancer.

Pages